Channel Wealth LLC Cuts Stake in Novo Nordisk A/S $NVO

Channel Wealth LLC trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 55.4% in the 4th quarter, Holdings Channel reports. The firm owned 9,178 shares of the company’s stock after selling 11,420 shares during the period. Channel Wealth LLC’s holdings in Novo Nordisk A/S were worth $467,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in NVO. Guerra Advisors Inc purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $25,000. Strengthening Families & Communities LLC purchased a new position in Novo Nordisk A/S during the 3rd quarter valued at about $30,000. WealthCollab LLC boosted its position in Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after buying an additional 260 shares during the period. American National Bank & Trust purchased a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $28,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $29,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on NVO. Kepler Capital Markets cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research started coverage on shares of Novo Nordisk A/S in a report on Thursday, March 26th. They set a “peer perform” rating for the company. Nordea Equity Research cut Novo Nordisk A/S to a “hold” rating in a research report on Tuesday, February 24th. CICC Research initiated coverage on shares of Novo Nordisk A/S in a report on Friday, January 9th. They issued an “outperform” rating and a $73.50 target price for the company. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 24th. Four analysts have rated the stock with a Buy rating, eighteen have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $46.02 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.57. The business’s fifty day moving average price is $38.71 and its 200 day moving average price is $46.97. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $81.44. The stock has a market capitalization of $205.47 billion, a PE ratio of 10.80, a price-to-earnings-growth ratio of 10.74 and a beta of 0.77.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, March 31st. The company reported $1.03 earnings per share (EPS) for the quarter. The company had revenue of $10.85 billion for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. Equities research analysts forecast that Novo Nordisk A/S will post 3.39 EPS for the current year.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill demand is surging, with reports of a “record-breaking” U.S. launch and more than 2 million prescriptions since January, strengthening confidence in Novo Nordisk’s growth outlook. Novo’s CEO champions “record-breaking start” for Wegovy pill in US market
• Positive Sentiment: Novo Nordisk raised its 2026 guidance after strong oral Wegovy prescriptions, suggesting the new formulation could offset some pricing pressure and support profits. Novo Nordisk Guidance Lift Tests Valuation As Oral Wegovy Demand Surges
• Positive Sentiment: Amazon is expanding access to Novo Nordisk’s Ozempic pill through same-day delivery and kiosks, which could broaden patient reach and improve adoption. Amazon Pharmacy Expands Access to New Ozempic® Pill via Same-Day Delivery, Kiosks
• Positive Sentiment: Analysts are lifting earnings estimates, reflecting confidence that the company’s recent momentum can carry into the next fiscal year. Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus (NVO)
• Neutral Sentiment: Novo’s India sales jumped after price cuts boosted demand, but the growth also highlights intensifying competition from cheaper GLP-1 alternatives in key international markets. Novo Nordisk’s Ozempic India Price Cut Boosts Obesity Drug Sales
• Neutral Sentiment: Broader investor focus remains on whether the Wegovy pill can expand the GLP-1 market enough to offset pricing pressure and competition from Eli Lilly. Novo and Lilly gain on signs weight-loss pills could expand the market
• Negative Sentiment: Generic Ozempic competition is beginning to emerge in Canada, raising concern that semaglutide revenue could weaken internationally over time. Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.